


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION TRANSMITTAL UNDER 37 CFR 1.53**



MAIL STOP SEQUENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing is the patent application of:

Title: MATERIALS AND METHODS RELATING TO THERAPY AND DIAGNOSIS
USING TARGETING OF CELLS THAT EXPRESS JPL POLYPEPTIDES


Inventor(s): Peter C. R. EMTAGE, Y. Tom TANG, Qing A. ZHAO, Chenghua LIU and
Radoje T. DRMANAC

- Applicant(s) hereby request(s) that the above-captioned application **NOT BE PUBLISHED** under 35 U.S.C. § 122(b) and 37 C.F.R. § 1.211. The undersigned hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Applicant(s) suggest(s) Figure * for inclusion on the front page of the patent application publication and patent

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this correspondence and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on **July 24, 2003**, in an envelope addressed to: Mail Stop SEQUENCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. EV 331 980 986 US.


Donna B. Rose

1. Type of application

This is a new utility application.

- Applicants claim small entity status (See 37 CFR 1.27).

2. Application Papers Enclosed

1 Title Page
168 Pages of Specification (excluding Claims, Abstract and Drawings)
7 Page(s) of Claims
1 Page(s) of Abstract
4 Sheet(s) of Drawings (Figs. 1-4) ● Formal ○ Informal
22 Page(s) of Sequence Listing

3. Oath or Declaration

- An executed declaration of the inventor(s) is enclosed.
- Unexecuted – the undersigned attorney or agent is authorized to file this application on behalf of the applicant(s). An executed declaration will follow.

4. Additional Papers Enclosed

- ☐ Preliminary Amendment
- ☐ Information Disclosure Statement
- ☐ Declaration of Biological Deposit
- ☒ Computer readable copy of sequence listing containing nucleotide and/or amino acid sequence (2 CD-ROMs)
- ☒ Statement Regarding Sequence Listing Under 37 CFR §1.821(f)
- ☒ Statement under 37 CFR §1.52(e)(3)
- ☐ Assignment Document with Assignment Recordation Cover Sheet
- ☐ A bibliographic data entry sheet
- ☐ Verified translation of a non-English patent application
- ☒ Return receipt postcard
- ☐ Other

5. Priority Applications Under USC 119

Certified copies of applications from which priority under 35 USC 119 is claimed are listed below and

- ☐ are attached.
- ☐ will follow

6. Filing Fee Calculation (37 CFR 1.16)

CLAIMS AS FILED – INCLUDING PRELIMINARY AMENDMENT (IF ANY)						
			SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
BASIC FEE				\$375.00		\$750.00
TOTAL	49-20	= 29	X 9 =	\$261.00	X 18 =	\$0.00
INDEP.	20-3	= 17	X 42 =	\$714.00	X 84 =	\$0.00
First Presentation of Multiple Dependent Claim			+ 140 =	\$140.00	+ 280 =	\$0.00
FILING FEE:				\$1,490.00	OR	\$0.00

B. ☐ Design Application (\$165.00/\$330.00) Filing Fee: \$ _____

C. ☐ Plant Application (\$260.00/\$520.00) Filing Fee: \$ _____

D. Other fees

☐ Recording Assignment [Fee -- \$40.00 per assignment] \$ _____

☐ Petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached [Fee -- \$130.00] \$ _____

TOTAL FEES ENCLOSED \$ 1,490.00

7. Method of Payments of Fees

☐ Enclosed check

Charge Deposit Account No. 501169. A duplicate copy of this transmittal is enclosed

8. Deposit Account and Refund Authorization

- The Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 501169. A duplicate copy of this transmittal is enclosed.

Please direct all future correspondence to Elena Quertermous at the address below.

Respectfully submitted,

Date: July 24, 2003

By: 

Elena Quertermous, Ph.D.
Agent for Applicants
Registration No. 47,873
Customer No. 34285
NUVELO, Inc.
675 Almanor Avenue
Sunnyvale, CA 94085
Tel.: (408) 215-4000
Fax: (408) 524-8145

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Peter C.R. Emtage et al.

Serial No: Not yet assigned


Filed: July 24, 2003

For: MATERIALS AND
METHODS RELATING TO
THERAPY AND
DIAGNOSIS USING
TARGETING OF CELLS
THAT EXPRESS JPL
POLYPEPTIDES

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence and any documents referred to as being enclosed therewith are being deposited with the U.S. Postal Service on **July 24, 2003**, in an envelope addressed to: Mail Stop SEQUENCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, utilizing the "Express Mail Post Office to Addressee" service of the U.S. Postal Service under Express Mail Label No. EV 331 980 986 US.

Name of Person signing Certificate: Donna B. Rose


Signature of Person Mailing

STATEMENT UNDER 37 CFR §1.52(e)(3)

MAIL STOP SEQUENCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

I hereby state the material on the paper copy and the compact disc contain the file named "JPL seq list.ST25final.txt", were created on an IBM PC, Windows 2000 operating system on July 23, 2003, 3:26:05 PM and contains a size of 48.0 KB (49,152 bytes).

Respectfully submitted,

Date: July 24, 2003

By:



Elena Quertermous, Ph.D.

Agent for Applicants

Registration No. 47,873

Customer No. 34285

NUVELO, Inc.

675 Almanor Avenue

Sunnyvale, CA 94085

Tel.: (408) 215-4000

Fax: (408) 524-8145